Dec 27, 2022 TWi Pharmaceuticals, Inc. (“TWi”) today announced the official launch of Sorafenib Tosylate Tablet (Equivalent to Nexavar®), via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., in partnership with Yabao Pharmaceutical Co., Ltd. Beijing. Product is available for immediate shipment.
 
 

Sorafenib Tosylate Tablet is used to treat patients with advanced hepatocellular carcinoma (HCC) that has spread to other parts of the body or cannot be treated with surgery and is not suitable for local treatment or with failure of local treatment; patients with a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. According to IQVIA data, the total sales of Sorafenib Tosylate Tablet in the US were approximately US$61 million for the 12 months ended October 2022.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, ophthalmic, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visitwww.twipharma.com